CYP17 genotype and breast cancer risk

Ainsley Weston, Ching Fei Pan, Ira J. Bleiweiss, H. Barbara Ksieski, Noah Roy, Nell Maloney Patel, Mary S. Wolff

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

The MspAI polymorphism in the 5' untranslated region of CYP17 has been evaluated as a breast cancer risk factor in a hospital-based case-control study in New York City. The study population consisted of 363 women [123 breast cancer patients and 240 patient controls (123 benign breast disease without atypical hyperplasia, 117 women without breast disease)]. There were 224 Caucasians (76 cases, 148 controls), 55 African-Americans (20 cases, 35 controls) and 84 Hispanics (27 cases, 57 controls); 142 premenopausal women and 221 postmenopausal women. Consistent with a previous report (Feigelson et el., Cancer Res., 57: 1063-1065, 1997) we found no evidence to implicate the minor variant (restriction site present allele, designated A2) as a breast cancer risk factor. Furthermore, we sought evidence to implicate the minor variant of CYP17 in the development of more aggressive breast cancers (n = 38/121) as had been reported previously. Although confidence intervals (CI) overlap, the data presented here do not provide support for previously reported findings (odds ratio, 0.9; 95% CI, 0.4-2.0; n = 38 versus odds ratio, 2.5; 95% CI, 1.1-5.2; n = 40). Clearly this question needs to be resolved in a larger study. No evidence was found to support the contention that inheritance of the minor variant is a predictor of early age at menarche. Allelic frequencies between different ethnic groups were not found to be different with the exception of Hispanic controls, in which the genotypic distribution was not consistent with the Hardy-Weinberg equilibrium.

Original languageEnglish (US)
Pages (from-to)941-944
Number of pages4
JournalCancer Epidemiology Biomarkers and Prevention
Volume7
Issue number10
StatePublished - Oct 1 1998
Externally publishedYes

Fingerprint

Steroid 17-alpha-Hydroxylase
Genotype
Breast Neoplasms
Breast Diseases
Confidence Intervals
Hispanic Americans
Odds Ratio
Menarche
5' Untranslated Regions
Ethnic Groups
varespladib methyl
African Americans
Hyperplasia
Case-Control Studies
Alleles
Population
Neoplasms

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Oncology

Cite this

Weston, A., Pan, C. F., Bleiweiss, I. J., Ksieski, H. B., Roy, N., Maloney Patel, N., & Wolff, M. S. (1998). CYP17 genotype and breast cancer risk. Cancer Epidemiology Biomarkers and Prevention, 7(10), 941-944.
Weston, Ainsley ; Pan, Ching Fei ; Bleiweiss, Ira J. ; Ksieski, H. Barbara ; Roy, Noah ; Maloney Patel, Nell ; Wolff, Mary S. / CYP17 genotype and breast cancer risk. In: Cancer Epidemiology Biomarkers and Prevention. 1998 ; Vol. 7, No. 10. pp. 941-944.
@article{0c64bfd92baa4f2da6f575950e91c251,
title = "CYP17 genotype and breast cancer risk",
abstract = "The MspAI polymorphism in the 5' untranslated region of CYP17 has been evaluated as a breast cancer risk factor in a hospital-based case-control study in New York City. The study population consisted of 363 women [123 breast cancer patients and 240 patient controls (123 benign breast disease without atypical hyperplasia, 117 women without breast disease)]. There were 224 Caucasians (76 cases, 148 controls), 55 African-Americans (20 cases, 35 controls) and 84 Hispanics (27 cases, 57 controls); 142 premenopausal women and 221 postmenopausal women. Consistent with a previous report (Feigelson et el., Cancer Res., 57: 1063-1065, 1997) we found no evidence to implicate the minor variant (restriction site present allele, designated A2) as a breast cancer risk factor. Furthermore, we sought evidence to implicate the minor variant of CYP17 in the development of more aggressive breast cancers (n = 38/121) as had been reported previously. Although confidence intervals (CI) overlap, the data presented here do not provide support for previously reported findings (odds ratio, 0.9; 95{\%} CI, 0.4-2.0; n = 38 versus odds ratio, 2.5; 95{\%} CI, 1.1-5.2; n = 40). Clearly this question needs to be resolved in a larger study. No evidence was found to support the contention that inheritance of the minor variant is a predictor of early age at menarche. Allelic frequencies between different ethnic groups were not found to be different with the exception of Hispanic controls, in which the genotypic distribution was not consistent with the Hardy-Weinberg equilibrium.",
author = "Ainsley Weston and Pan, {Ching Fei} and Bleiweiss, {Ira J.} and Ksieski, {H. Barbara} and Noah Roy and {Maloney Patel}, Nell and Wolff, {Mary S.}",
year = "1998",
month = "10",
day = "1",
language = "English (US)",
volume = "7",
pages = "941--944",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

Weston, A, Pan, CF, Bleiweiss, IJ, Ksieski, HB, Roy, N, Maloney Patel, N & Wolff, MS 1998, 'CYP17 genotype and breast cancer risk', Cancer Epidemiology Biomarkers and Prevention, vol. 7, no. 10, pp. 941-944.

CYP17 genotype and breast cancer risk. / Weston, Ainsley; Pan, Ching Fei; Bleiweiss, Ira J.; Ksieski, H. Barbara; Roy, Noah; Maloney Patel, Nell; Wolff, Mary S.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 7, No. 10, 01.10.1998, p. 941-944.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CYP17 genotype and breast cancer risk

AU - Weston, Ainsley

AU - Pan, Ching Fei

AU - Bleiweiss, Ira J.

AU - Ksieski, H. Barbara

AU - Roy, Noah

AU - Maloney Patel, Nell

AU - Wolff, Mary S.

PY - 1998/10/1

Y1 - 1998/10/1

N2 - The MspAI polymorphism in the 5' untranslated region of CYP17 has been evaluated as a breast cancer risk factor in a hospital-based case-control study in New York City. The study population consisted of 363 women [123 breast cancer patients and 240 patient controls (123 benign breast disease without atypical hyperplasia, 117 women without breast disease)]. There were 224 Caucasians (76 cases, 148 controls), 55 African-Americans (20 cases, 35 controls) and 84 Hispanics (27 cases, 57 controls); 142 premenopausal women and 221 postmenopausal women. Consistent with a previous report (Feigelson et el., Cancer Res., 57: 1063-1065, 1997) we found no evidence to implicate the minor variant (restriction site present allele, designated A2) as a breast cancer risk factor. Furthermore, we sought evidence to implicate the minor variant of CYP17 in the development of more aggressive breast cancers (n = 38/121) as had been reported previously. Although confidence intervals (CI) overlap, the data presented here do not provide support for previously reported findings (odds ratio, 0.9; 95% CI, 0.4-2.0; n = 38 versus odds ratio, 2.5; 95% CI, 1.1-5.2; n = 40). Clearly this question needs to be resolved in a larger study. No evidence was found to support the contention that inheritance of the minor variant is a predictor of early age at menarche. Allelic frequencies between different ethnic groups were not found to be different with the exception of Hispanic controls, in which the genotypic distribution was not consistent with the Hardy-Weinberg equilibrium.

AB - The MspAI polymorphism in the 5' untranslated region of CYP17 has been evaluated as a breast cancer risk factor in a hospital-based case-control study in New York City. The study population consisted of 363 women [123 breast cancer patients and 240 patient controls (123 benign breast disease without atypical hyperplasia, 117 women without breast disease)]. There were 224 Caucasians (76 cases, 148 controls), 55 African-Americans (20 cases, 35 controls) and 84 Hispanics (27 cases, 57 controls); 142 premenopausal women and 221 postmenopausal women. Consistent with a previous report (Feigelson et el., Cancer Res., 57: 1063-1065, 1997) we found no evidence to implicate the minor variant (restriction site present allele, designated A2) as a breast cancer risk factor. Furthermore, we sought evidence to implicate the minor variant of CYP17 in the development of more aggressive breast cancers (n = 38/121) as had been reported previously. Although confidence intervals (CI) overlap, the data presented here do not provide support for previously reported findings (odds ratio, 0.9; 95% CI, 0.4-2.0; n = 38 versus odds ratio, 2.5; 95% CI, 1.1-5.2; n = 40). Clearly this question needs to be resolved in a larger study. No evidence was found to support the contention that inheritance of the minor variant is a predictor of early age at menarche. Allelic frequencies between different ethnic groups were not found to be different with the exception of Hispanic controls, in which the genotypic distribution was not consistent with the Hardy-Weinberg equilibrium.

UR - http://www.scopus.com/inward/record.url?scp=0031661073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031661073&partnerID=8YFLogxK

M3 - Article

C2 - 9796640

AN - SCOPUS:0031661073

VL - 7

SP - 941

EP - 944

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 10

ER -

Weston A, Pan CF, Bleiweiss IJ, Ksieski HB, Roy N, Maloney Patel N et al. CYP17 genotype and breast cancer risk. Cancer Epidemiology Biomarkers and Prevention. 1998 Oct 1;7(10):941-944.